[go: up one dir, main page]

JO3317B1 - مركبات تترا هيدروبيرولو ثيازين - Google Patents

مركبات تترا هيدروبيرولو ثيازين

Info

Publication number
JO3317B1
JO3317B1 JOP/2014/0061A JOP20140061A JO3317B1 JO 3317 B1 JO3317 B1 JO 3317B1 JO P20140061 A JOP20140061 A JO P20140061A JO 3317 B1 JO3317 B1 JO 3317B1
Authority
JO
Jordan
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
compound
formula
Prior art date
Application number
JOP/2014/0061A
Other languages
English (en)
Inventor
Morgan Watson Brian
James Mergott Dustin
James Green Steven
Larry Winneroski Leonard Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3317B1 publication Critical patent/JO3317B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركب وفقًا للصيغة I: حيث تكون R عبارة عن H أو F؛ و تكون A عبارة عن: أو ملح مقبول صيدليًا منه.
JOP/2014/0061A 2013-03-12 2014-02-27 مركبات تترا هيدروبيرولو ثيازين JO3317B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
JO3317B1 true JO3317B1 (ar) 2019-03-13

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0061A JO3317B1 (ar) 2013-03-12 2014-02-27 مركبات تترا هيدروبيرولو ثيازين

Country Status (38)

Country Link
US (3) US8841293B1 (ar)
EP (1) EP2970336B1 (ar)
JP (1) JP6095844B2 (ar)
KR (1) KR101688761B1 (ar)
CN (1) CN105026404B (ar)
AP (1) AP2015008713A0 (ar)
AR (1) AR094918A1 (ar)
BR (1) BR112015018738A8 (ar)
CA (1) CA2898500C (ar)
CL (1) CL2015002529A1 (ar)
CR (1) CR20150418A (ar)
CY (1) CY1119585T1 (ar)
DK (1) DK2970336T3 (ar)
EA (1) EA026006B1 (ar)
ES (1) ES2653421T3 (ar)
HK (1) HK1212694A1 (ar)
HR (1) HRP20171851T1 (ar)
HU (1) HUE037487T2 (ar)
IL (1) IL240903B (ar)
JO (1) JO3317B1 (ar)
LT (1) LT2970336T (ar)
MA (1) MA38390B1 (ar)
ME (1) ME02910B (ar)
MX (1) MX2015012628A (ar)
MY (1) MY180083A (ar)
NO (1) NO3039297T3 (ar)
NZ (1) NZ712207A (ar)
PE (1) PE20151542A1 (ar)
PH (1) PH12015502031B1 (ar)
PL (1) PL2970336T3 (ar)
PT (1) PT2970336T (ar)
RS (1) RS56645B1 (ar)
SG (1) SG11201507499XA (ar)
SI (1) SI2970336T1 (ar)
TN (1) TN2015000340A1 (ar)
TW (1) TWI593692B (ar)
UA (1) UA112941C2 (ar)
WO (1) WO2014143579A1 (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY180688A (en) 2012-06-13 2020-12-07 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
HUE031764T2 (en) 2012-10-26 2017-07-28 Lilly Co Eli Tetrahydropyrrolothiazine derivatives as BACE inhibitors
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
WO2015078803A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
AU2015238537B2 (en) 2014-03-26 2019-08-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
AU2015238541B2 (en) 2014-03-26 2019-09-19 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103406A1 (es) 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
CA2991612A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
BR112018006024A2 (pt) 2015-09-24 2020-05-12 F. Hoffmann-La Roche Ag Compostos bicíclicos como inibidores de atx
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
MA50007A (fr) 2016-12-15 2021-04-07 Amgen Inc Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
US10889581B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
MA54100A (fr) 2016-12-15 2021-10-20 Amgen Inc Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MX2019007100A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
JP7177773B2 (ja) 2016-12-15 2022-11-24 アムジエン・インコーポレーテツド β-セクレターゼ阻害剤としてのオキサジン誘導体および使用方法
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003082856A1 (en) * 2002-03-22 2003-10-09 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
MX2007016180A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
WO2007049532A1 (ja) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
AU2009205072C1 (en) * 2008-01-18 2016-10-13 Eisai R & D Management Co., Ltd. Condensed aminodihydrothiazine derivative
JP2011518225A (ja) 2008-04-22 2011-06-23 シェーリング コーポレイション Bace−1阻害剤としてのフェニル置換2−イミノ−3−メチルピロロピリミジノン化合物、組成物、およびそれらの使用
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
US20110207723A1 (en) 2008-09-30 2011-08-25 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071109A1 (ja) 2009-12-11 2011-06-16 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
PH12015502031A1 (en) 2016-01-18
HK1212694A1 (zh) 2016-06-17
BR112015018738A8 (pt) 2018-01-23
PL2970336T3 (pl) 2018-03-30
AR094918A1 (es) 2015-09-09
SI2970336T1 (sl) 2017-11-30
NZ712207A (en) 2019-09-27
NO3039297T3 (ar) 2018-03-10
CN105026404A (zh) 2015-11-04
CN105026404B (zh) 2016-11-23
ME02910B (me) 2018-04-20
TN2015000340A1 (en) 2017-01-03
EA026006B1 (ru) 2017-02-28
US8987254B2 (en) 2015-03-24
EP2970336B1 (en) 2017-10-04
KR101688761B1 (ko) 2016-12-21
EA201591491A1 (ru) 2016-01-29
TW201520217A (zh) 2015-06-01
RS56645B1 (sr) 2018-03-30
TWI593692B (zh) 2017-08-01
SG11201507499XA (en) 2015-10-29
JP2016512252A (ja) 2016-04-25
AU2014228351A1 (en) 2015-09-17
CA2898500A1 (en) 2014-09-18
EP2970336A1 (en) 2016-01-20
US8841293B1 (en) 2014-09-23
HUE037487T2 (hu) 2018-08-28
MA38390B1 (fr) 2020-01-31
IL240903B (en) 2018-12-31
MA38390A1 (fr) 2018-08-31
WO2014143579A1 (en) 2014-09-18
UA112941C2 (uk) 2016-11-10
ES2653421T3 (es) 2018-02-07
DK2970336T3 (da) 2017-11-13
US20140275044A1 (en) 2014-09-18
PH12015502031B1 (en) 2016-01-18
KR20150119070A (ko) 2015-10-23
IL240903A0 (en) 2015-10-29
CY1119585T1 (el) 2018-03-07
PE20151542A1 (es) 2015-10-28
CA2898500C (en) 2017-11-14
JP6095844B2 (ja) 2017-03-15
MX2015012628A (es) 2016-07-07
LT2970336T (lt) 2018-01-10
CL2015002529A1 (es) 2016-03-28
HRP20171851T1 (hr) 2018-01-12
CR20150418A (es) 2015-09-16
US20150157641A1 (en) 2015-06-11
AP2015008713A0 (en) 2015-09-30
PT2970336T (pt) 2017-12-21
BR112015018738A2 (pt) 2017-07-18
US20140350245A1 (en) 2014-11-27
MY180083A (en) 2020-11-20

Similar Documents

Publication Publication Date Title
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
NZ714283A (en) Novel histone deacetylase inhibitors
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12016500169A1 (en) Polymorph of syk inhibitors
IN2015DN00598A (ar)
PH12017501523A1 (en) Selective bace1 inhibitors
RS54730B1 (sr) Inhibitori beta sekretaze
EA201690911A1 (ru) Соединения диметилбензойной кислоты
JO3318B1 (ar) مثبطات bace
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
EA201690894A1 (ru) Феноксиэтилы
IN2014DN07996A (ar)
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
GB201020397D0 (en) Compounds
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EA201690593A1 (ru) Новые соединения мочевины
MX2015012610A (es) Pacritinib deuterizado.
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof